BACKGROUND: In the 2008 World Health Organization classification, small lymphocytic lymphoma is defined as a neoplasm with the tissue morphology and immunophenotype of chronic lymphocytic leukemia, but with absence of leukemia. Minimal criteria of tissue involvement to separate small lymphocytic lymphoma from monoclonal B-cell lymphocytosis have not been defined. DESIGN AND METHODS: We reviewed the clinicopathological features of 36 patients with extramedullary tissue biopsies containing chronic lymphocytic leukemia-type cells and less than 5×10(9)/L peripheral blood monoclonal B cells. Pathological features (extent and patterns of involvement, architectural preservation, presence of proliferation centers) as well as cytogenetic and radiological findings were examined in relation to clinical outcome. RESULTS: The biopsies were performed to evaluate lymphadenopathy in 20 patients and for other reasons (most frequently staging of a non-hematologic neoplasm) in 16 patients. At latest follow-up (median 23 months), 21 untreated patients had no or stable lymphadenopathy, 3 had regressed lymphadenopathy, and 12 had developed progressive lymphadenopathy and/or received therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma. Features associated with progression/treatment included lymph nodes 1.5 cm or greater on imaging studies (P=0.01) and presence of proliferation centers in the biopsied tissue (P=0.004). Neither the size nor extent of involvement of the excised lymph node correlated with progression/treatment. CONCLUSIONS: Our findings suggest that biopsies containing chronic lymphocytic leukemia-type cells, but lacking proliferation centers and with non-enlarged or only slightly enlarged lymph nodes on imaging, represent a very indolent disease that may best be considered a tissue equivalent of monoclonal B-cell lymphocytosis rather than overt small lymphocytic lymphoma. We propose that such cases be designated as tissue involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma-like cells of uncertain significance.
BACKGROUND: In the 2008 World Health Organization classification, small lymphocytic lymphoma is defined as a neoplasm with the tissue morphology and immunophenotype of chronic lymphocytic leukemia, but with absence of leukemia. Minimal criteria of tissue involvement to separate small lymphocytic lymphoma from monoclonal B-cell lymphocytosis have not been defined. DESIGN AND METHODS: We reviewed the clinicopathological features of 36 patients with extramedullary tissue biopsies containing chronic lymphocytic leukemia-type cells and less than 5×10(9)/L peripheral blood monoclonal B cells. Pathological features (extent and patterns of involvement, architectural preservation, presence of proliferation centers) as well as cytogenetic and radiological findings were examined in relation to clinical outcome. RESULTS: The biopsies were performed to evaluate lymphadenopathy in 20 patients and for other reasons (most frequently staging of a non-hematologic neoplasm) in 16 patients. At latest follow-up (median 23 months), 21 untreated patients had no or stable lymphadenopathy, 3 had regressed lymphadenopathy, and 12 had developed progressive lymphadenopathy and/or received therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma. Features associated with progression/treatment included lymph nodes 1.5 cm or greater on imaging studies (P=0.01) and presence of proliferation centers in the biopsied tissue (P=0.004). Neither the size nor extent of involvement of the excised lymph node correlated with progression/treatment. CONCLUSIONS: Our findings suggest that biopsies containing chronic lymphocytic leukemia-type cells, but lacking proliferation centers and with non-enlarged or only slightly enlarged lymph nodes on imaging, represent a very indolent disease that may best be considered a tissue equivalent of monoclonal B-cell lymphocytosis rather than overt small lymphocytic lymphoma. We propose that such cases be designated as tissue involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma-like cells of uncertain significance.
Authors: Wendy G Nieto; Julia Almeida; Alfonso Romero; Cristina Teodosio; Antonio López; Ana F Henriques; Maria Luz Sánchez; María Jara-Acevedo; Ana Rasillo; Marcos González; Paulino Fernández-Navarro; Tomás Vega; Alberto Orfao Journal: Blood Date: 2009-05-06 Impact factor: 22.113
Authors: Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Sarah S Fung; Kortney L Hillier; Chantal S Leger; Irwin Sandhu; Linda M Vickars; Paul F Galbraith; Charles H Li; Heather A Leitch Journal: Leuk Lymphoma Date: 2007-06
Authors: Andy C Rawstron; Fiona L Bennett; Sheila J M O'Connor; Marwan Kwok; James A L Fenton; Marieth Plummer; Ruth de Tute; Roger G Owen; Stephen J Richards; Andrew S Jack; Peter Hillmen Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Tait D Shanafelt; Neil E Kay; Greg Jenkins; Timothy G Call; Clive S Zent; Diane F Jelinek; William G Morice; Justin Boysen; Liam Zakko; Susan Schwager; Susan L Slager; Curtis A Hanson Journal: Blood Date: 2008-11-17 Impact factor: 22.113
Authors: Karthik A Ganapathi; Stefania Pittaluga; Oreofe O Odejide; Arnold S Freedman; Elaine S Jaffe Journal: Haematologica Date: 2014-09 Impact factor: 9.941
Authors: Joel F Gradowski; Rachel L Sargent; Fiona E Craig; Kathleen Cieply; Kim Fuhrer; Carol Sherer; Steven H Swerdlow Journal: Am J Clin Pathol Date: 2012-07 Impact factor: 2.493
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Steven H Swerdlow; Isinsu Kuzu; Ahmet Dogan; Stephan Dirnhofer; John K C Chan; Birgitta Sander; German Ott; Luc Xerri; Leticia Quintanilla-Martinez; Elias Campo Journal: Virchows Arch Date: 2015-10-10 Impact factor: 4.064